Abstract: Provided herein are microbial infection indicator devices, including dressing with indicators, standalone indicator inserts or disks that can be freely placed at a wound site or dressing, and applications thereof for displaying a visible or detectable signal to a user upon detection of an analyte or biomarker indicative of an infection, such as a color change.

Abstract: The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Abstract: Provided herein are microbial infection indicator devices, including dressing with indicators, standalone indicator inserts or disks that can be freely placed at a wound site or dressing, and applications thereof for displaying a visible or detectable signal to a user upon detection of an analyte or biomarker indicative of an infection, such as a color change.

Abstract: A method for selecting a compound or a composition suitable for treating lipofuscin associated diseases in a patient, the method including the steps of determining a reactivity factor, determining a targeting factor that allows an uptake into a cell and a provides a targeting of lipofuscin, and selecting a compound or a composition or combining compounds to obtain a compound or composition that comprises a reactivity factor and an targeting factor.

Abstract: Provided herein are microbial infection indicator devices, including dressing with indicators, standalone indicator inserts or disks that can be freely placed at a wound site or dressing, and applications thereof for displaying a visible or detectable signal to a user upon detection of an analyte or biomarker indicative of an infection, such as a color change.

Abstract: A method for selecting a compound or a composition suitable for treating lipofuscin associated diseases in a patient, the method including the steps of determining a reactivity factor, determining a targeting factor that allows an uptake into a cell and a provides a targeting of lipofuscin, and selecting a compound or a composition or combining compounds to obtain a compound or composition that comprises a reactivity factor and an targeting factor.

Abstract: The present invention is directed to sulphated compounds comprising at least one glycosidic amine group, and polysaccharide, oligosaccharide, peptide and protein derivatives comprising such compounds, and mixtures thereof. The present invention is also directed to methods of synthesizing such compounds. Such compounds may bind to a range of proteins, find application in methods of modifying, or testing for a modification in the level of a cytokine in vivo, ex vivo or in vitro, and find application in the treatment and/or prevention of inflammation, an inflammatory disorder, a proliferative disorder, an immune disorder, an angiogenesis-dependent disorder, a sensitivity disorder, an adverse endocrine reaction, a degenerative disorder, wound healing, depression, and other diseases and disorders.

Abstract: The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.

Abstract: This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Abstract: The invention relates to 2-thio-substituted imidazole derivatives of the Formula I, and to methods of use thereof.

Abstract: The present invention is directed to sulphated compounds comprising at least one glycosidic amine group, and polysaccharide, oligosaccharide, peptide and protein derivatives comprising such compounds, and mixtures thereof. The present invention is also directed to methods of synthesising such compounds. Such compounds may bind to a range of proteins, find application in methods of modifying, or testing for a modification in the level of a cytokine in vivo, ex vivo or in vitro, and find application in the treatment and/or prevention of inflammation, an inflammatory disorder, a proliferative disorder, an immune disorder, an angiogenesis-dependent disorder, a sensitivity disorder, an adverse endocrine reaction, a degenerative disorder, wound healing, depression, and other diseases and disorders.

Abstract: The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.

Abstract: The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.

Abstract: The invention relates to 2-thio-substituted imidazole derivatives of the Formula I, and to methods of use thereof.

Abstract: The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and are therefore suitable to treat disorders of the rheumatic type and to prevent allergically induced diseases. The macrolide conjugates have significantly enhanced potency and efficacy.

Abstract: This invention features a compound of the following formula: T-(-L-C)m, T is a transportophore, L is a bond or a linker having a molecular weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1, 2, 3, 4, 5, 6, 7, or 8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2.

Abstract: This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Abstract: This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Abstract: This invention features a compound of the following formula: wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agent via the bond or the linker, and the transportophore is an azithromycin derivative or crown ether derivative.

Abstract: Functionalized polymers are mixed with pesticides to form semi-stable complexes with desirable field properties: reduced leaching in soil, improved leaf retention (rainfastness), selective unloading to roots and convenient packaging and application. Pesticides that may be so complexed include herbicides, insecticides (including compounds controlling non-insect arthropods and nematodes), bacteriocides, rodenticides, and fungicides. Polymers with which they may be complexed include derivatives of carbohydrates, amides, imines, alkanes, vinyls, styrenes or glycols. The polymers may be functionalized with chemical groups that exhibit ionic (amines, carboxyls), hydrophobic, complexing (e.g. metal chelating) and ligand binding interactions. The variously functionalized polymers may be mixed, grafted, or fused to obtain optimal properties. The polymer/pesticide formulations may be applied as granules, as suspensions or solutions in sprays, as foams, or as coats for seeds and fertilizers.